Showing results (121-130 of 172) with videos related to
Sort By:
Pageof 18
Cardiovascular Endocrinology & Metabolism|August 24, 2023
Mineralocorticoid receptor antagonists in cardiovascular translational biologyRobert J Chilton, José Silva-CardosoCardiovascular Endocrinology & Metabolism|October 2, 2023
The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonistsKazuo Kobayashi, Masao Toyoda, Nobuo Hatori, et al.Cardiovascular Endocrinology & Metabolism|August 18, 2020
Prevention and management of cardiovascular disease in patients with diabetes: current challenges and opportunitiesDennis Bruemmer, Steven E NissenCardiovascular Endocrinology & Metabolism|June 30, 2026
Effect of glucagon-like peptide-1 receptor agonists on major adverse cardiovascular events in adults with type 2 diabetes and established atherosclerotic cardiovascular disease: systematic review and meta-analysis of randomised trialsAlejandro Montenegro-Avila, Abelardo Montenegro-Cantillo, Jheyson Fuentes, et al.Cardiovascular Endocrinology & Metabolism|July 24, 2026
Association of diabetes and smoking with stroke subtypes and mortality in a Saudi cohortHussain Almohammed, Lama Alrashidi, Husna Irfan Thalib, et al.Cardiovascular Endocrinology & Metabolism|January 13, 2025
The interplay of heart rate variability and ventricular repolarization parameters in the obese state: a reviewAkash Tomar, Himani Ahluwalia, S Ramkumar, et al.Cardiovascular Endocrinology & Metabolism|November 14, 2025
High sensitivity C-reactive protein subsequent rise in urine albumin/creatinine ratio/fall in estimated glomerular filtration rate over 24 years in people with type 2 diabetesSangeeth Veulchamy, Andreas Matheou, Orestis Zavlis, et al.Cardiovascular Endocrinology & Metabolism|September 22, 2025
BRIDGE-DS study: a multicenter, observational, retrospective analysis of dapagliflozin and sitagliptin combination on modifiable cardiovascular risk factors in T2DM patients with ASCVD or high cardiovascular riskNaveen Bhamri, Ashutosh Kumar, Chandrakant Mishra, et al.Cardiovascular Endocrinology & Metabolism|September 22, 2025
Glucagon-like peptide-1 receptor agonists and obesity paradox in heart failure with preserved ejection fraction: a systematic reviewDarshan Hullon, Karolina Janiec, Violetta Florova, et al.Cardiovascular Endocrinology & Metabolism|January 26, 2023
Relationship between the triglyceride-glucose index and the SYNTAX score 2 in patients with non-ST elevation myocardial infarctionOnur Baydar, Alparslan Kilic, Erol GursoyPageof 18